We describe the clinical history of five patients from three Italian institutions treated with gilteritinib for R/R FLT3-mutated AML, who developed ICH soon after exposure to the drug (some characteristics of these patients are summarized in Table 1). The gene discussed is FLT3; the disease is acute myeloid leukemia.